Creators of Cycloset®*, the first and only FDA approved sympatholytic dopamine D2 receptor agonist for the treatment of type 2 diabetes.
*See full prescribing info

Veroscience > News > VeroScience Continues Clinical Evaluation of Bromocriptine-QR (Cycloset) and Neurophysiological Investigations of Brain Dopamine Regulation of Metabolism with Eight Papers Presented at the 2015 American Diabetes Association
News

VeroScience Continues Clinical Evaluation of Bromocriptine-QR (Cycloset) and Neurophysiological Investigations of Brain Dopamine Regulation of Metabolism with Eight Papers Presented at the 2015 American Diabetes Association

June 6, 2015 By Vera
This article is sourced from an external publication. Read the original →

http://www.prnewswire.com/news-releases/veroscience-continues-clinical-evaluation-of-bromocriptine-qr-cycloset-and-neurophysiological-investigations-of-brain-dopamine-regulation-of-metabolism-with-eight-papers-presented-at-the-2015-american-diabetes-association-confer-300095056.html

Website by Axxiem
© Copyright . All Right Reserved